Stockhead’s Ashtyn Hiron sits down with Aroa Biosurgery (ASX:ARX) CEO Brian Ward to close the books on 2023 and gain a sneak peek into what’s around the corner.

Aroa found itself kicking goals last year with evidence its Myriad treatment is effective in trauma surgery for tissue repair and complex wounds.

“We started off doing a lot of small procedures and lower limb reconstruction and we had a lot more focus on trauma over the last 6-7 months,” Ward said.

“The rate of healing has been really impressive – these wounds have been at 100% granulated within 23 days.”

Tune in to hear what’s coming up for Aroa Biosurgery in 2024.

Read MoreHealth

Featured Companies

You might be interested in